MSLNAMA-CD3L2K

MSLNAMA-CD3L2K appears to be a code name for an investigational or preclinical drug, likely a bi-specific antibody or T-cell engager targeting **mesothelin (MSLN)** and **CD3**. This type of agent typically works by binding to mesothelin (a cell surface protein overexpressed in several solid tumors, including mesothelioma, ovarian, and pancreatic cancers) on tumor cells and CD3 on T cells, thereby directing and activating T cells to attack mesothelin-expressing cancer cells. The "L2K" likely indicates a specific antibody format or engineering modification. No clinical trial or commercial information for MSLNAMA-CD3L2K is available in the current search results or recognized drug/clinical trial registries, implying it is in early-stage research or preclinical development.

Other names

MSLN/CD3-targeting BsAbamatuximab-blinatumomab bispecific antibody